| [1] |
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 2012, 142: 1592-1609.
|
| [2] |
Baran B, Akyuz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?. World J Gastroenterol, 2014, 20: 14219-14229.
|
| [3] |
Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol, 2012, 27: 420-428.
|
| [4] |
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol, 2013, 10: 330-344.
|
| [5] |
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003, 37: 917-923.
|
| [6] |
de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol, 2008, 48 (Suppl 1): S104-112.
|
| [7] |
Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129: 113-121.
|
| [8] |
Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology, 2010, 51: 595-602.
|
| [9] |
Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol, 2010, 53: 372-384.
|
| [10] |
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med, 2010, 363: 1341-1350.
|
| [11] |
Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J, 2008, 72: 618-625.
|
| [12] |
Treeprasertsuk S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int, 2012, 32: 945-950.
|
| [13] |
Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol, 2012, 10: 646-650.
|
| [14] |
Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011, 43: 617-649.
|
| [15] |
Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab, 2007, 92: 3490-3497.
|
| [16] |
Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017,66:1138-1153.
|
| [17] |
Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis, 2009, 203: 581-586.
|
| [18] |
Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation, 2005, 112: 666-673.
|
| [19] |
Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation, 2006, 114: 1761-1791.
|
| [20] |
Targher G, Chonchol M, Miele L, et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost, 2009, 35: 277-287.
|
| [21] |
Acikel M, Sunay S, Koplay M, et al. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg, 2009, 9: 273-279.
|
| [22] |
Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol, 2008, 49: 600-607.
|
| [23] |
Ferrara LA, Cardoni O, Mancini M, et al. Metabolic syndrome and left ventricular hypertrophy in a general population.Results from the Gubbio Study. J Hum Hypertens, 2007, 21: 795-801.
|
| [24] |
Fallo F, Dalla Pozza A, Sonino N, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis, 2009, 19: 646-653.
|
| [25] |
Yilmaz Y, Kurt R, Yonal O, et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis, 2010, 211: 182-186.
|
| [26] |
Bhatia LS, Curzen NP, Calder PC, et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J, 2012, 33: 1190-1200.
|
| [27] |
Korenblat KM, Fabbrini E, Mohammed BS, et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology, 2008, 134: 1369-1375.
|
| [28] |
Li XL, Sui JQ, Lu LL, et al. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis, 2016, 15: 53.
|
| [29] |
Lonardo A, Sookoian S, Pirola CJ, et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism, 2016, 65: 1136-1150.
|
| [30] |
Lin JS, O′Connor E, Evans CV, et al. Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the US Preventive Services Task Force. Ann Intern Med, 2014, 161: 568-578.
|
| [31] |
Arab JP, Candia R, Zapata R, et al. Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol, 2014, 20: 12182-12201.
|
| [32] |
Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol, 2015, 62(1 Suppl): S65-75.
|
| [33] |
Lonardo A, Ballestri S, Targher G, et al. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol, 2015, 9: 629-650.
|
| [34] |
Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol, 2013, 168: 3846-3852.
|
| [35] |
Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet, 2010, 376: 1916-1922.
|
